Description
If you intend to take dutasteride-based drugs to treat baldness, then first you need to consult your therapist and trichologist. Dutahair can not be taken by women and children.
What is Dutahair?
Dutahair (Dutasteride) is a 5-alpha-reductase inhibitor of the first and second type, which is used to treat prostatic adenoma. It is also used to stop hair loss in androgenetic alopecia. In contrast to finasteride inhibits both types of 5-alpha-reductase.
How does dutasteride differ from finasteride?
Finasteride inhibits 5-alpha reductase of the second type, while the first type remains untouched. Dutasteride inhibits both types of 5-alpha reductase, which can significantly improve the therapeutic effect, since the first type is about 30% of the total 5-alpha reductase. If a particular person has the first type of 5-alpha reductase more active than the second type or if the sensitivity of the receptors is high, then even these 30% percent can play a big role in the treatment of alopecia.
What dutasteride-based drugs are used?
Avodart is a drug containing 0.5 mg of dutasteride in each tablet. Manufactured by GlaxoSmithKline. It is used to treat prostate adenoma. There is no official analogue for the treatment of alopecia, as in the case of finasteride (Propecia). But this does not prevent the use of an avtoart to stop hair loss. There is also an Indian analog of Avodarta – Duprost (Duprost), which is manufactured by Cipla. Each capsule contains 0.5 mg of dutasteride.
How is Dutahair taken to treat baldness?
Take 0.1 mg of dutasteride 3 times a week and 4 times 0.5 mg finasteride every other day. This scheme allows you to achieve good results and reduce side effects, which we will talk about separately. Ie, the avtopart tablet is divided into 5 parts. A suitable dosage can also be determined based on the graphs of dihydrotestosterone level changes, which are presented below.
Dutahair is better taken on an empty stomach, it provides an increase in blood concentration by 10-15%.
How do the levels of dihydrotestosterone decrease when taking dutasteride and finasteride?
Studies show that 0.1 mg of Dutahair reduces the level of dihydrosterone similarly to 5.0 mg of finasteride, which is approximately -70%. This graph shows the levels of dihydrotestosterone in the blood with placebo, finasteride (5 mg) and dutasteride at various dosages (0.5 mg and 5 mg). As can be seen, the dosage of dutasteride increases by a factor of 10 only (from 0.5 mg to 5 mg) in effectiveness only by a few percent. The vertical dotted line indicates the stopping time of the medication. As can be seen 16 weeks after stopping dutasteride at a dose of 5 mg, the level of DHT in the blood only slightly increased.
But the most interesting is the following chart. It shows not only how the level of DHT varies with the dose of dutasteride, but also the levels of the 5-alpha reductase of the first and second types. As can be seen, a dose of 0.1 mg per day has virtually no effect on the level of 5-alpha reductase of the first type, while the level of the second type has significantly decreased. It is difficult to judge the veracity and reliability of this chart: it is unclear what is behind Gl198745 and why the concentrations of dutasteride are printed on top of another font.
How does Dutahair affect hair density?
If you believe this schedule (the original source of Avodart ), 0.1 mg of dutasteride is similar in effectiveness to 5 mg of finasteride and on average provides you with +72 hair for a round area of the scalp with a diameter of 2.54 cm (1 inch). Measurements on this graph were made 6 months after the start of treatment. A dose of dutasteride of 0.5 mg daily provides +92 hair for a similar skin area.
What side effects can occur?
Among the possible side effects are: impotence, a decrease in sexual desire, a decrease in the amount of eaculant, gynecomastia (growth of the sexual glands by female type), allergic reactions (skin rash, itching, hives, localized edema).
Monotherapy with dutasteride
Approximately 19% of the 2,167 patients who used dutasteride in a two-year, placebo-controlled Phase III clinical trial experienced adverse events during the first year of treatment. Most adverse reactions were mild or moderate and affected the reproductive system.
In the course of a further two-year, open, extended study, no changes in the profile of adverse reactions were identified.
The following table describes adverse reactions from controlled clinical trials and post-marketing follow-up: The adverse reactions listed below, which the investigator believes are associated with taking the drug (the incidence of at least 1%) during the first year of treatment were more frequent in patients in the group , taking dutasteride, than in the group taking placebo. On adverse reactions during post-marketing studies reported in spontaneous reports, so the actual frequency of reactions is not known.
Combined therapy with dutasteride and tamsulosin L
A four-year study of CombAT, in which 0.5 mg (n = 1623) monotherapy with dutasteride was compared once a day with tamsulosin monotherapy 0.4 mg (n = 1611) once a day and with combination therapy (n = 1610), showed that the incidence of adverse reactions, which the investigator believed to be associated with treatment, was 22%, 6%, 4%, and 2% for combination dutasteride / tamsulosin therapy, respectively, during the first, second, third and fourth years of treatment, respectively %, 6%, 3% and 2% for monotherapy with dutasteride and 13%, 5%, 2% and 2% for tamsulo therapy in winter. The higher incidence of adverse reactions during the first year of treatment in the combination therapy group was associated with a higher incidence of abnormalities in the reproductive system, in particular, with ejaculatory abnormalities observed in this group.
